Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells

Heaney, N. B. et al. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115(11), pp. 2241-2250. (doi: 10.1182/blood-2008-06-164582)

Full text not currently available from Enlighten.

Abstract

Chronic myeloid leukemia (CML) is treated effectively with tyrosine kinase inhibitors (TKIs); however, 2 key problems remain-the insensitivity of CML stem and progenitor cells to TKIs and the emergence of TKI-resistant BCR-ABL mutations. BCR-ABL activity is associated with increased proteasome activity and proteasome inhibitors (PIs) are cytotoxic against CML cell lines. We demonstrate that bortezomib is antiproliferative and induces apoptosis in chronic phase (CP) CD34(+) CML cells at clinically achievable concentrations. We also show that bortezomib targets primitive CML cells, with effects on CD34(+)38(-), long-term culture-initiating (LTC-IC) and nonobese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cells. Bortezomib is not selective for CML cells and induces apoptosis in normal CD34(+)38(-) cells. The effects against CML cells are seen when bortezomib is used alone and in combination with dasatinib. Bortezomib causes proteasome but not BCR-ABL inhibition and is also effective in inhibiting proteasome activity and inducing apoptosis in cell lines expressing BCR-ABL mutations, including T315I. By targeting both TKI-insensitive stem and progenitor cells and TKI-resistant BCR-ABL mutations, we believe that bortezomib offers a potential therapeutic option in CML. Because of known toxicities, including myelosuppression, the likely initial clinical application of bortezomib in CML would be in resistant and advanced disease. (Blood. 2010;115:2241-2250)

Item Type:Articles
Keywords:Apoptosis BCR-ABL MUTATIONS BLOOD CANCER CELLS Chronic CHRONIC MYELOGENOUS LEUKEMIA chronic myeloid leukemia CHRONIC-PHASE CML DASATINIB BMS-354825 DISEASE DRUG-RESISTANCE GENE HEMATOPOIETIC-CELLS INHIBITOR Leukaemia LONG-TERM MULTIPLE-MYELOMA Myeloid NF-KAPPA-B PATIENTS RECEIVING IMATINIB PHASE-I Proteasome PROTEASOME INHIBITOR BORTEZOMIB Scotland TYROSINE KINASE INHIBITOR tyrosine kinase inhibitors
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Jorgensen, Dr Heather and Pellicano, Dr Francesca and Heaney, Dr Nicholas and Allan, Mrs Elaine
Authors: Heaney, N. B., Pellicano, F., Zhang, B., Crawford, L., Chu, S., Kazmi, S. M. A., Allan, E. K., Jorgensen, H. G., Irvine, A. E., Bhatia, R., and Holyoake, T. L.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Blood
Publisher:American Society of Hematology
ISSN:0006-4971
ISSN (Online):1528-0020

University Staff: Request a correction | Enlighten Editors: Update this record